Overview
Status
Active
Registry date
2026-08-24
Share capital
10,000.00 PLN
Activity description
Emergopharm is a pharmaceutical company providing research, development and supply services for medical devices, dietary supplements and cosmetics. It supplies products and services to small, medium-sized and multinational companies, including finished products, custom development and contract manufacturing.
Industry
Offer
- Medicinal products and supplements
- Dermatological products
- Vitamin products
- Probiotic products
- Gynecological products
- Pediatric products
- Custom product development
- Contract manufacturing
Certifications: GMP, HACCP, ISO 13485
Website technology
- Online shop
- WooCommerce
- Website
- WordPress
Authorized Representatives
Mariusz Radosław Cięciaraage 47 – President of the Management Board
Manner of representation
Each member of the management board is authorised to make declarations of will on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Felix Familia Fundacja Rodzinna | 189 | $2,552.67 | 94.5% |
Others | 11 | $148.57 | 5.5% |
Beneficial owners
| Person | Rights |
|---|---|
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Sep 24, 2026 | Transformation registered |
Public aid
5 public aid cases recorded, with a total value of $150,328.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | –– | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | –– | Prezes Zakładu Ubezpieczeń Społecznych | |
| Apr 28, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | –– | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2019-05-01 | Participation of EMERGOPHARM in the BIOTECHNOLOGY AND PHARMACEUTICALS promotion programme to expand into new foreign markets | $78,505$78,505 | Operational Programme Smart Growth | |
| 2018-03-01 | Obtaining industrial property protection for an invention in the form of a pharmaceutical composition containing totarol as an active ingredient to counteract disturbances in the composition of the vaginal microbiota | $65,963$65,963 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Lubelskie Zakłady Farmaceutyczne PolfaS.A. | $7,449,773.98 | polfa.pl | ||
| MargomedS.A. | $6,360,594.28 | margomed.com | ||
| Infimedsp. z o.o. | $5,587,133.78 | infimed.pl | ||
| CM InternationalS.A. | $4,905,625.86 | cos-medico.eu | ||
| Bifarmsp. z o.o. | $1,858,549.39 | bifarm.pl | ||
| Pulmeqsp. z o.o. | $1,126,185.54 | pulmeq.com | ||
| BIO 3d Solutionssp. z o.o. | $11,692.51 | bio3dsolutions.com |
FAQ
Last updated: 2026-08-27